Optimized Treatment Starts With Molecular Testing in NSCLC
January 14th 2022Konstantinos Arnaoutakis, MD, discusses new strategies in the management of ALK-positive non–small cell lung cancer, frontline immunotherapy, targeting EGFR, and biomarkers and targeted therapies in early-stage and advanced disease.
Multidisciplinary Effort Key to Successful Lung Cancer Screening Programs
Mollie Meek, MD, highlights key lung cancer screening trials, offered insight into how to successfully implement an effective program, and stressed that collaboration is critical in order to provide the best patient care.